Engineered bacteria expressing cytolysin (ClyA) were used for the targeted treatment of pancreatic cancer [113], which was able to accumulate significantly and specifically in anaerobic tumor tissues and stimulate tumor immunity with infiltration of immune cells such as neutrophils, macrophages, CD4+, CD8+, and T lymphocytes. Here, PRF1 is linked to neoplasm.